Background Malignant pleural mesothelioma (MPM) is a locally aggressive disease with a
poor prognosis. After failure of first line platinum-based chemotherapy, there is no widely …

TPS8577 Background: Mesothelin is highly expressed in epithelioid mesothelioma.
Amatuximab is a chimeric monoclonal antibody that binds to mesothelin. Amatuximab was …

Background The combination of pembrolizumab, an anti-PD-1 antibody, and lenvatinib, an
antiangiogenic multikinase inhibitor, shows synergistic activity in preclinical and clinical …

Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …

Malignant pleural mesothelioma is a rare cancer that is typically associated with exposure to
asbestos. Patients with malignant pleural mesothelioma have poor outcomes with …

Methods Adult patients with previously untreated, unresectable, histologically confirmed
MPM and ECOG performance status 0–1 were randomized (1: 1; stratified by histology …

A systematic review and meta-analysis of surgical treatments for malignant pleural
mesothelioma showed that median overall survival ranged between 13 and 29months for …

Objectives Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer with a
poor prognosis and limited treatment options. This study assessed the characteristics …

Aim To evaluate the real‐world treatment patterns and outcomes for patients with pleural
mesothelioma (PM) in the era of immunotherapy. Methods This retrospective audit included …

Background Malignant pleural mesothelioma (MPM) is an aggressive malignancy
characterised by limited treatment options and a poor prognosis. At relapse after platinum …